keyword
https://read.qxmd.com/read/38656653/systematic-literature-review-on-the-incidence-of-herpes-zoster-in-populations-at-increased-risk-of-disease-in-the-eu-eea-switzerland-and-the-uk
#1
JOURNAL ARTICLE
Alen Marijam, Nikki Vroom, Amit Bhavsar, Inga Posiuniene, Nicolas Lecrenier, Hilde Vroling
INTRODUCTION: Older adults and patients with underlying conditions such as immunocompromised (IC) populations (e.g., due to medical conditions or immunosuppressive medication) are at increased risk for herpes zoster (HZ). The first HZ recombinant vaccine for IC patients was approved in 2020. Limited evidence exists to inform decision-makers on HZ incidence in high-risk patients in Europe. This systematic literature review (SLR) assessed HZ incidence across 14 high-risk populations in the European Union/European Economic Area, Switzerland, and the United Kingdom...
April 24, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38653955/outcome-of-human-parainfluenza-virus-infection-in-allogeneic-stem-cell-transplantation-recipients-possible-impact-of-ribavirin-therapy
#2
JOURNAL ARTICLE
Ariadna Pérez, Juan Montoro, Pedro Chorão, Dolores Gómez, Manuel Guerreiro, Estela Giménez, Marta Villalba, Jaime Sanz, Rafael Hernani, Juan Carlos Hernández-Boluda, Ignacio Lorenzo, David Navarro, Carlos Solano, Per Ljungman, José Luis Piñana
BACKGROUND: This retrospective study focused on analyzing community-acquired respiratory virus (CARV) infections, in particular human parainfluenza virus (hPIV) after allogeneic stem cell transplant (allo-SCT) in adults recipients. It aimed to assess the impact of ribavirin treatment, clinical characteristics, and risk factors associated with lower respiratory tract disease (LRTD) progression and all-cause mortality. PATIENTS AND METHODS: The study included 230 allo-SCT recipients diagnosed with hPIV between December 2013 and June 2023...
April 24, 2024: Infection
https://read.qxmd.com/read/38644612/extramedullary-infiltration-in-pediatric-acute-myeloid-leukemia-results-from-the-therapeutically-applicable-research-to-generate-effective-treatments-target-initiative
#3
JOURNAL ARTICLE
Weiya Li, Mingyue Shi, Pan Zhou, Ying Liu, Xiaobo Liu, Xingjun Xiao, Suqiong Zuo, Yanliang Bai, Kai Sun
BACKGROUND: The outcome of extramedullary infiltration (EMI) in pediatric acute myeloid leukemia (AML) is controversial, and little is known about the implications of stem cell transplantation (SCT) and gemtuzumab ozogamicin (GO) treatment on patients with EMI. METHODS: We retrieved the clinical data of 713 pediatric patients with AML from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) dataset, and analyzed the clinical and prognostic characteristics of patients with EMI at diagnosis and relapse...
April 21, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38610955/donor-lymphocyte-infusion-in-the-treatment-of-post-transplant-relapse-of-acute-myeloid-leukemias-and-myelodysplastic-syndromes-significantly-improves-overall-survival-a-french-italian-experience-of-134-patients
#4
JOURNAL ARTICLE
Eugenia Accorsi Buttini, Cristina Doran, Michele Malagola, Vera Radici, Marco Galli, Vicky Rubini, Alessandro Leoni, Mirko Farina, Nicola Polverelli, Federica Re, Simona Bernardi, Mohamad Mohty, Domenico Russo, Eolia Brissot
BACKGROUND: Disease relapse after allogeneic stem cell transplantation (allo-SCT) is the main challenge for curing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We investigated the overall survival (OS) after allo-SCT relapse according to different therapeutic approaches. METHODS: We analyzed 134 patients who relapsed after allo-SCT performed between 2015 and 2021 at Saint-Antoine University Hospital, Paris and Spedali Civili di Brescia, Brescia...
March 26, 2024: Cancers
https://read.qxmd.com/read/38607399/long-term-outcomes-after-haploidentical-stem-cell-transplantation-for-hematologic-malignancies
#5
JOURNAL ARTICLE
Supawee Saengboon, Stefan O Ciurea, Uday R Popat, Jeremy Leon Ramdial, Qaiser Bashir, Amin Majid Alousi, Julianne Chen, Gabriela Rondon, Amanda L Olson, Jim S Im, Chitra Hosing, Elizabeth J Shpall, Richard E Champlin, Samer A Srour
The introduction of posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis lead to significant improvements in haploidentical stem cell transplantation (haplo-SCT) outcomes over the past decade. We retrospectively assessed long-term outcomes of patients who had their first haplo-SCT between February 2009 and March 2019. Long-term survivors were defined as patients who were alive and disease free at 2 years after transplant. Three hundred thirty-five patients with a median age of 48 (range, 18-72) years were identified...
March 23, 2024: Blood Advances
https://read.qxmd.com/read/38602169/haploidentical-hematopoietic-stem-cell-transplantation-with-busulfan-cyclophosphamide-and-fludarabine-conditioning-for-x-linked-adrenal-cerebral-leukodystrophy
#6
JOURNAL ARTICLE
Yao Chen, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Kai-Yan Liu, Jiong Qing, Yan-Ling Yang, Xiao-Jun Huang
OBJECTIVE: We investigated the safety and efficacy of haploidentical stem cell transplantation (SCT) in pediatric patients with X-linked adrenoleukodystrophy (ALD). METHODS: A retrospective analysis of transplantation data from 29 cases of ALD, treated between December 2014 and April 2022, was conducted. Neurologic function scores (NFS) were assessed. The conditioning regimen was busulfan 9.6 mg/kg, cyclophosphamide 200 mg/kg, and fludarabine 90 mg/m2 (BFC)...
May 2024: Pediatric Transplantation
https://read.qxmd.com/read/38597118/real-world-patient-characteristics-treatment-patterns-and-treatment-outcomes-of-patients-with-diffuse-large-b-cell-lymphoma-by-line-of-therapy
#7
JOURNAL ARTICLE
Helmneh M Sineshaw, Christina M Zettler, Jennifer Prescott, Mahek Garg, Samhita Chakraborty, Eric M Sarpong, Claire Bai, Andrew J Belli, Laura L Fernandes, Ching-Kun Wang
BACKGROUND: Although initial treatment of diffuse large B-cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) can be effective, up to 50% of patients will develop refractory or relapsed (R/R) disease. This study aimed to provide contemporary data on characteristics, treatment patterns, and outcomes for R/R-DLBCL. METHODS: Patients with incident (January 2016 to March 2021) DLBCL age ≥18 years who initiated first-line (1L) therapy were identified from the COTA real-world database...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38595814/prostate-cancer-research-tools-cell-types-and-molecular-targets
#8
REVIEW
Alvin Y Liu
Multiple cancer cell types are found in prostate tumors. They are either luminal-like adenocarcinoma or less luminal-like and more stem-like non-adenocarcinoma and small cell carcinoma. These types are lineage related through differentiation. Loss of cancer differentiation from luminal-like to stem-like is mediated by the activation of stem cell transcription factors (scTF) such as LIN28A, NANOG, POU5F1 and SOX2. scTF expression leads to down-regulation of β2-microglobulin (B2M). Thus, cancer cells can change from the <mml:math xmlns:mml="https://www...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38587600/comparative-assessment-of-quality-of-life-among-adolescents-with-sickle-cell-disease-and-sickle-cell-trait-evidence-from-odisha-india
#9
JOURNAL ARTICLE
Basanta Kumar Bindhani, Jayanta Kumar Nayak
The present study aims to assess the quality of life (QOL) of adolescents with sickle cell disease (SCD) and sickle cell trait (SCT) in hard-to-reach regions in Koraput district of Odisha state. 387 adolescents with sickle cell genes (HbSS = 52, HbAS = 135, HbA = 200) were selected through their medical records from southern parts of Odisha. A validated and pretested QOL scale was modified to assess the QOL. The questionnaires were modified by aiming to describe the proportion of adolescents who feel restricted in different domains, measuring the extent within each domain, and finding an aggregate score of QOL...
April 8, 2024: Journal of Community Genetics
https://read.qxmd.com/read/38581695/prognostic-impact-of-number-of-induction-courses-to-attain-complete-remission-in-patients-with-acute-myeloid-leukemia-transplanted-with-either-a-matched-sibling-or-human-leucocyte-antigen-10-10-or-9-10-unrelated-donor-an-acute-leukemia-working-party-european
#10
JOURNAL ARTICLE
Justin Loke, Myriam Labopin, Charles Craddock, Gérard Socié, Tobias Gedde-Dahl, Didier Blaise, Edouard Forcade, Urpu Salmenniemi, Anne Huynh, Jurjen Versluis, Ibrahim Yakoub-Agha, Hélène Labussière-Wallet, Johan Maertens, Jakob Passweg, Claude Eric Bulabois, Ludovic Gabellier, Stephan Mielke, Cristina Castilla-Llorente, Eric Deconinck, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
INTRODUCTION: For the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission. METHODS: This Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)-matched unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ)...
April 6, 2024: Cancer
https://read.qxmd.com/read/38553383/donor-genetic-determinant-of-thymopoiesis-rs2204985-and-stem-cell-transplantation-outcome-in-a-multipopulation-cohort
#11
JOURNAL ARTICLE
Julia Nihtilä, Urpu Salmenniemi, Maija Itälä-Remes, Rachel E Crossland, David Gallardo, Katarzyna Bogunia-Kubik, Piotr Łacina, Maria Bieniaszewska, Sebastian Giebel, Kati Hyvärinen, Eliisa Kekäläinen, Jarmo Ritari, Jukka Partanen
BACKGROUND: A genetic polymorphism, rs2204985, has been reported to be associated with the diversity of T-cell antigen receptor repertoire and TREC levels, reflecting the function of the thymus. As the thymus function can be assumed to be an important factor regulating the outcome of stem cell transplantation (SCT), it was of great interest that rs2204985 showed a genetic association to disease-free and overall survival in a German SCT donor cohort. Tools to predict the outcome of SCT more accurately would help in risk assessment and patient safety...
March 28, 2024: Human Immunology
https://read.qxmd.com/read/38526221/performance-of-noninvasive-prenatal-screening-for-fetal-sex-chromosome-aneuploidies-in-a-cohort-of-116-862-pregnancies
#12
JOURNAL ARTICLE
Yanfei Xu, Jianbo Lou, Yeqing Qian, Pengzhen Jin, Yangwen Qian, Jiawei Hong, Yuqing Xu, Yixuan Yin, Songjia Yi, Minyue Dong
BACKGROUND: Noninvasive prenatal screening (NIPS) has shown good performance in screening common aneuploidies. However, its performance in detecting fetal sex chromosome aneuploidies (SCAs) needs to be evaluated in a large cohort. RESEARCH DESIGN AND METHODS: In this retrospective observation, a total of 116,862 women underwent NIPS based on DNA nanoball sequencing from 2015 to 2022. SCAs were diagnosed based on karyotyping or chromosomal microarray analysis (CMA)...
March 25, 2024: Expert Review of Molecular Diagnostics
https://read.qxmd.com/read/38519312/sarcopenia-with-decreased-total-psoas-muscle-area-in-children-with-high-risk-neuroblastoma
#13
JOURNAL ARTICLE
Min-Jung Bang, Sanghoon Lee, Ji Won Lee, Wontae Kim, Ki Woong Sung, Jeong-Meen Seo
BACKGROUND: We calculated psoas muscle area (PMA) z-scores in high-risk neuroblastoma patients undergoing treatment to examine the clinical significance of sarcopenia in this cohort. METHODS: We analyzed retrospective data from patients aged 0-18 who were diagnosed with abdominal neuroblastoma between 2005 and 2019 at Samsung Medical Center. Patients categorized as high-risk undergone induction chemotherapy, neuroblastoma excision, and tandem high-dose chemotherapy with autologous stem cell transplantation (HDCT/auto-SCT) were selected...
March 21, 2024: Asian Journal of Surgery
https://read.qxmd.com/read/38513813/predictors-of-cytomegalovirus-reactivation-after-allogeneic-hematopoietic-cell-transplantation-insights-from-a-real-world-experience
#14
JOURNAL ARTICLE
Matthew McGuirk, Moazzam Shahzad, Muhammad Kashif Amin, Muhammad Atif Khan, Polina Bellman, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Forat Lutfi, Nausheen Ahmed, Rajat Bansal, Haitham Abdelhakim, Chelsea Gorsline, Dennis Matthew Shoemaker, Al-Ola Abdallah, Leyla Shune, Sunil H Abhyankar, Anurag K Singh, Joseph P McGuirk, Muhammad Umair Mushtaq
BACKGROUND: We aimed to investigate factors associated with cytomegalovirus (CMV) viremia and CMV disease and its impact on post-transplant outcomes including overall survival (OS) following allogeneic hematopoietic stem cell transplantation (Allo-SCT). METHODS: We conducted a single-center retrospective study including 452 Allo-SCT recipients (matched unrelated donor, MUD 61%; haploidentical, haplo 39%) from 2016 to 2021. Data were analyzed using SPSS v28. Descriptive (chi-square and t-test), Kaplan-Meier and regression analyses were conducted...
March 19, 2024: Transplant Immunology
https://read.qxmd.com/read/38512100/the-malignant-potential-of-ovarian-steroid-cell-tumors-revisited-a-multi-institutional-clinicopathologic-analysis-of-115-cases
#15
JOURNAL ARTICLE
Oluwole Fadare, Elmira Vaziri Fard, Rohit Bhargava, Mohamed Mokhtar Desouki, Krisztina Z Hanley, Philip P C Ip, Joshua J X Li, Bingjian Lu, Fabiola Medeiros, Joshua Hoi Yan Ng, Vinita Parkash, Andre Pinto, Charles M Quick, Stephanie L Skala, Minami Tokuyama, Gulisa Turashvili, Christina H Wei, Deyin Xing, Wenxin Zheng, T Rinda Soong, Brooke E Howitt
Steroid cell tumors (SCTs) of the ovary are rare and understudied, and as such, uncertainties remain about their malignant potential, as well as clinicopathologic predictors of patient outcome. Based on a multi-institutional cohort of cases, we present findings from the largest study of SCT reported to date. Clinicopathologic data were documented on 115 cases of SCT that were assembled from 17 institutions. The median patient age was 55 years (range: 9 to 84). When measured, preoperative androgen levels were elevated in 84...
March 21, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38506145/letermovir-use-may-impact-on-the-cytomegalovirus-dna-fragmentation-profile-in-plasma-from-allogeneic-hematopoietic-stem-cell-transplant-recipients
#16
JOURNAL ARTICLE
Estela Giménez, Roberto Gozalbo-Rovira, Eliseo Albert, José Luis Piñana, Carlos Solano, David Navarro
Cytomegalovirus (CMV) DNA in plasma is mainly unprotected and highly fragmented. The size of the amplicon largely explains the variation in CMV DNA loads quantified across PCR platforms. In this proof-of-concept study, we assessed whether the CMV DNA fragmentation profile may vary across allogeneic hematopoietic stem cell transplant recipients (allo-SCT), within the same patient over time, or is affected by letermovir (LMV) use. A total of 52 plasma specimens from 14 nonconsecutive allo-SCT recipients were included...
March 2024: Journal of Medical Virology
https://read.qxmd.com/read/38504993/impact-of-melphalan-day-1-vs-day-2-on-outcomes-after-autologous-stem-cell-transplant-for-multiple-myeloma
#17
JOURNAL ARTICLE
Aimee Merino, Ryan Shanley, Faridullah Rashid, Jenna Langer, Michelle Dolan, Sarah Tu, Najla El Jurdi, John Rogosheske, Kirollos Hanna, Todd DeFor, Murali Janakiram, Daniel Weisdorf
BACKGROUND: Melphalan is the most common conditioning regimen used prior to autologous stem cell transplant (ASCT); however, there are varying data on optimal melphalan timing prior to transplant for best safety and efficacy. Historically, ASCT conditioning consisted of melphalan 200 mg/m2 on day 2 (D-2) (48 h prior to ASCT), but many institutions have since adopted a melphalan protocol with administration on day 1 (D-1) (24 h prior to SCT) or split dosing over the 2 days. The optimal timing of melphalan has yet to be determined...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38497679/hla-haploidentical-stem-cell-transplantation-in-children-with-inherited-bone-marrow-failure-syndromes-a-retrospective-analysis-on-behalf-of-ebmt-severe-aplastic-anemia-and-pediatric-diseases-working-parties
#18
JOURNAL ARTICLE
Stefano Giardino, Dirk-Jan Eikema, Brian Piepenbroek, Mattia Algeri, Mouhab Ayas, Maura Faraci, Abdelghani Tbakhi, Marco Zecca, Mohammed Essa, Bénédicte Neven, Yves Bertrand, Gaurav Kharya, Tatiana Bykova, Sarah Lawson, Mario Petrini, Alexander Mohseny, Fanny Rialland, Beki James, Anca Colita, Mony Fahd, Simone Cesaro, Ansgar Schulz, Katharina Kleinschmidt, Krzysztof Kałwak, Selim Corbacioglu, Carlo Dufour, Antonio Risitano, Régis Peffault de Latour
Haploidentical stem cell transplantation (haplo-SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I-BMF) lacking a matched donor. This retrospective study, conducted on behalf of the EBMT SAAWP and PDWP, aims to report the current outcomes of haplo-SCT in I-BMFs, comparing the different in vivo and ex vivo T-cell depletion approaches. One hundred and sixty-two I-BMF patients who underwent haplo-SCT (median age 7.4 years) have been registered. Fanconi Anemia was the most represented diagnosis (70...
March 18, 2024: American Journal of Hematology
https://read.qxmd.com/read/38486828/autologous-hematopoietic-stem-cell-transplant-at-a-tertiary-care-centre-in-india-achieving-comparable-outcomes-with-adaptations
#19
JOURNAL ARTICLE
Aditya Kumar Gupta, Jagdish Prasad Meena, Rachna Seth, Priyanka Naranje, Sujata Mohanty, Poonam Coshic
Autologous stem cell transplantation (ASCT) is the standard treatment for many high-risk solid tumors. Patients undergoing ASCT should be managed in a dedicated hematopoietic stem cell transplantation (HSCT) unit with isolation rooms, high-efficiency particulate air (HEPA) filters, and positive pressure. We report the outcomes of the first 20 pediatric patients who underwent ASCT in isolation rooms with no HEPA filters or positive pressure. Moreover, the isolation rooms were not part of a dedicated HSCT unit...
February 25, 2024: Blood Cell Ther
https://read.qxmd.com/read/38480852/treatment-pattern-and-outcomes-of-re-induction-therapy-prior-to-stem-cell-transplantation-in-patients-with-relapsed-refractory-multiple-myeloma-in-germany
#20
JOURNAL ARTICLE
Sandra Sauer, Monika Engelhardt, Karolin Trautmann-Grill, Christoph Kimmich, Mathias Hänel, Martin Schmidt-Hieber, Hans Salwender, Carmen Flossmann, Hiltrud Heckmann, Franziska Ertel, Andrea Friederich, Sachin Patel, Barbara Thun, Marc S Raab
There are limited data guiding choice of re-induction therapies for patients with relapsed/refractory multiple myeloma (RRMM) prior to stem cell transplantation (SCT). We performed a retrospective medical chart review of 171 patients with RRMM in Germany who received re-induction therapy in second line (78%; n = 134) or third line (22%; n = 37) prior to re-SCT. Index therapy was defined as first completed re-induction therapy for planned myeloablative conditioning and SCT in second/third line within the eligibility period (1/2016-12/2019)...
March 14, 2024: Bone Marrow Transplantation
keyword
keyword
163403
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.